Literature DB >> 8306090

Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.

R G Pertwee1, L A Stevenson, G Griffin.   

Abstract

1. Mice pretreated intraperitoneally for 2 days with delta-9-tetrahydrocannabinol (delta-9-THC) at a dose of 20 mg kg-1 day-1 and then challenged intravenously with this drug, 24 h after the second pretreatment, showed a 6 fold tolerance to the hypothermic effect of delta-9-THC. This pretreatment also induced tolerance to the hypothermic effects of the cannabimimetic agents, CP 55,940 (4.6 fold) and WIN 55,212-2 (4.9 fold), but not to the hypothermic effect of the putative endogenous cannabinoid, anandamide. 2. Vasa deferentia removed from mice pretreated intraperitoneally with delta-9-THC twice at a dose of 20 mg kg-1 day-1 were less sensitive to its inhibitory effect on electrically-evoked contractions than vasa deferentia obtained from control animals. The cannabinoid pretreatment induced a 30 fold parallel rightward shift in the lower part of the concentration-response curve of delta-9-THC and a marked reduction in the maximal inhibitory effect of the drug. It also induced tolerance to the inhibitory effects on the twitch response of CP 55,940 (8.7 fold), WIN 55,212-2 (9.6 fold) and anandamide (12.3 fold). 3. The results confirm that cannabinoid tolerance can be rapid in onset and support the hypothesis that it is mainly pharmacodynamic in nature. The finding that in vivo pretreatment with delta-9-THC can produce tolerance not only to its own inhibitory effect on the vas deferens but also to that of three other cannabimimetic agents, suggests that this tissue would be suitable as an experimental model for investigating the mechanisms responsible for cannabinoid tolerance. 4. Further experiments are required to establish why tolerance to anandamide-induced hypothermia was not produced by a pretreatment with delta-9-THC that did induce tolerance to the hypothermic effects of delta-9-THC, CP 55,940 and WIN 55,212-2 and to the inhibitory effects of delta-9-THC,CP 55,940, WIN 55,212-2 and anandamide on the twitch response of the vas deferens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8306090      PMCID: PMC2175863          DOI: 10.1111/j.1476-5381.1993.tb13989.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Effects of delta9-tetrahydrocannabinol on the rates of oxygen consumption of mice.

Authors:  R G Pertwee; R Tavendale
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

2.  Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.

Authors:  B R Martin; D R Compton; B F Thomas; W R Prescott; P J Little; R K Razdan; M R Johnson; L S Melvin; R Mechoulam; S J Ward
Journal:  Pharmacol Biochem Behav       Date:  1991-11       Impact factor: 3.533

Review 3.  The evidence for the existence of cannabinoid receptors.

Authors:  R Pertwee
Journal:  Gen Pharmacol       Date:  1993-07

4.  Enhancement of the hypothermic response of mice to delta-9-tetrahydrocannabinol by subhypothermic doses of chlorpromazine and phentolamine.

Authors:  G A Gray; D Hedley; R G Pertwee
Journal:  Neuropharmacology       Date:  1987 Feb-Mar       Impact factor: 5.250

5.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

6.  Synthesis and pharmacological evaluation of ether and related analogues of delta 8-, delta 9-, and delta 9,11-tetrahydrocannabinol.

Authors:  D R Compton; W R Prescott; B R Martin; C Siegel; P M Gordon; R K Razdan
Journal:  J Med Chem       Date:  1991-11       Impact factor: 7.446

7.  Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine.

Authors:  R G Pertwee; L A Stevenson; D B Elrick; R Mechoulam; A D Corbett
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

8.  Aminoalkylindoles: actions on specific G-protein-linked receptors.

Authors:  M Pacheco; S R Childers; R Arnold; F Casiano; S J Ward
Journal:  J Pharmacol Exp Ther       Date:  1991-04       Impact factor: 4.030

9.  Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol.

Authors:  A G Fitton; R G Pertwee
Journal:  Br J Pharmacol       Date:  1982-02       Impact factor: 8.739

10.  Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles.

Authors:  E M Jansen; D A Haycock; S J Ward; V S Seybold
Journal:  Brain Res       Date:  1992-03-13       Impact factor: 3.252

View more
  25 in total

Review 1.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

2.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

3.  Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner.

Authors:  S Tai; W S Hyatt; C Gu; L N Franks; T Vasiljevik; L K Brents; P L Prather; W E Fantegrossi
Journal:  Pharmacol Res       Date:  2015-09-08       Impact factor: 7.658

4.  Evaluation of fatty acid amides in the carrageenan-induced paw edema model.

Authors:  Laura E Wise; Roberta Cannavacciulo; Benjamin F Cravatt; Billy F Martin; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

5.  Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips.

Authors:  Fabio Guagnini; Paola Cogliati; Sylvain Mukenge; Gianfranco Ferla; Tiziano Croci
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

Review 6.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

7.  Analgesic tolerance to morphine is regulated by PPARγ.

Authors:  Giordano de Guglielmo; Marsida Kallupi; Giulia Scuppa; Serena Stopponi; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

8.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

9.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

10.  Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist.

Authors:  Terry Luk; Wenzhen Jin; Alexander Zvonok; Dai Lu; Xin-Zhong Lin; Charles Chavkin; Alexandros Makriyannis; Ken Mackie
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.